TUCSON, Ariz., July 22, 2025 — Stakeholders across the life sciences ecosystem are invited to attend the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC), taking place Sept. 9–11 ...

TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...

Critical Path Institute's ® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...

The Tucson-based Critical Path Institute was founded in 2005 as a public-private partnership with the U.S. Food and Drug Administration. Its main goal is to improve the drug-development process so ...

Digital pathology and artificial intelligence are transforming the drug development landscape, accelerating the path to ...

Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...